ENJAYMO® (sutimlimab-jome)

Time to talk about your comeback from CAD with ENJAYMO

Whether you're starting ENJAYMO or considering treatment, here are some resources to help you get the answers you need.

HOW MUCH ARE YOU IMPACTED BY FATIGUE?

People living with CAD may feel the impact of chronic fatigue caused by anemia in a variety of ways, including affecting their physical health and daily routine.

Use the sliders below to explore the impact of fatigue with our calculator.*

On average, how many days (0-7) per week are you impacted by fatigue in the following areas:

How many days do you have trouble staying awake during the day?

How many days do you struggle to carry out everyday or routine activities?

How many days does fatigue impact your ability to start a new task?

How many days are you too fatigued to finish a task?

How many days do you need someone's help to complete your usual activities because of your fatigue?

Based on your answers, fatigue affects you 0 out of 7 days per week on average.

Your Fatigue Time

0 OUT OF 7 DAYS WITH FATIGUE

That's equivalent to:

DAYS A MONTH

DAYS A YEAR

^*This calculator is provided for self-reflection and is not a diagnostic tool. Your healthcare professional is the best source of information regarding your health. Please consult your healthcare professional if you have any questions about your health or treatment.

HOW MUCH TIME DOES INFUSING WITH ENJAYMO TAKE?

ENJAYMO is given as an intravenous (IV) infusion weekly for the first 2 weeks, and then every 2 weeks thereafter.

Infusion with ENJAYMO usually takes 1 to 2 hours. After your first infusion, you will be monitored for up to 2 hours for possible infusion or allergic reactions. After all future infusions, you will be monitored for 1 hour. After being initiated on ENJAYMO, your infusions occur 1 day every 2 weeks**

1 DAY EVERY 2 WEEKS
AFTER INITIATION ON ENJAYMO

Following initiation, infusions should occur:

DAYS A MONTH

DAYS A YEAR

^**This time may vary between individuals and does not account for outside factors such as travel to and from infusion facilities, preparation for treatment, monitoring, additional labs, or doctor’s visits due to side effects of treatment. Be sure to speak with your healthcare provider with any questions you may have regarding infusions.

ADDRESSING THE IMPACT OF CAD WITH ENJAYMO

If your body destroys red blood cells faster than it can replace them, it can lead to anemia. It’s this chronic anemia that causes fatigue in CAD patients. ENJAYMO addresses the source of fatigue by helping stop hemolysis in its tracks.

SIGNIFICANT IMPROVEMENT IN FATIGUE

Patients on ENJAYMO were asked about the impact of fatigue on a scale of 0 (not at all) to 4 (very much so) for a total of 52 points. This 13-item survey (FACIT) included questions like:

How fatigued they felt

Frustration because of tiredness

Need to take a nap to get through the day

How weak and tired they felt

Ability to do usual activities

In the clinical trial, patients on ENJAYMO had an average 11-point improvement from baseline (improving from an average baseline score of 31.67 points to an average score at treatment assessment of 42.5 points) vs a 2-point improvement in patients on placebo. Higher scores on the survey meant a person felt less fatigue.

Doctor Discussion Guide

Use this guide to have a productive conversation with your doctor or healthcare team to see if ENJAYMO is right for you.

Your guide to enjaymo

Find out more information about CAD and ENJAYMO to help you get started.

Blood lab card

Because CAD is associated with colder temperatures, it's extremely important that your blood stays warm. Use this card to help ensure that healthcare providers and support staff are handling your blood properly.

Blood Test Tracker

This useful tracker will help you stay on top of your blood test results and any changes you feel in your body. Knowing what to monitor and what your levels are is important for both you and your doctor when managing CAD.

ENJAYMO ENROLLMENT FORM

If you've been prescribed ENJAYMO, work with your doctor to complete the ENJAYMO Patient Solutions Enrollment Form to get started with support services that are available to you.

Doctor Discussion Guide

Use this guide to have a productive conversation with your doctor or healthcare team to see if ENJAYMO is right for you.

Your guide to enjaymo

Find out more information about CAD and ENJAYMO to help you get started.

Blood lab card

Blood Test Tracker

ENJAYMO ENROLLMENT FORM

if you've been prescribed ENJAYMO, work with your doctor to complete the ENJAYMO Patient Solutions Enrollment Form to get started with support services that are available to you.

Connecting with the community

Various advocacy groups exist that offer support for patients living with CAD and the people involved in their care. A few examples are:

Cold Agglutinin Disease Foundation

National Organization for Rare Disorders (NORD)

Global Genes

Autoimmune Association

There are a number of organizations dedicated to providing information and support to people living with CAD and other rare disorders. This listing is provided as a resource only and does not constitute an endorsement by Sanofi of any particular organization or its programming. Additional resources on this topic may be available and should be investigated. Sanofi does not review or control the content of non-Sanofi websites.

INDICATION

ENJAYMO^® is a prescription medicine used to treat the breakdown of red blood cells (hemolysis) in adults with cold agglutinin disease (CAD).

It is not known if ENJAYMO is safe and effective in children.

INDICATION

IMPORTANT SAFETY INFORMATION

Do not receive ENJAYMO if you are allergic to sutimlimab-jome or any of the ingredients in ENJAYMO.

ENJAYMO can cause serious side effects, including:

Serious Infections: ENJAYMO is a prescription medicine that affects your immune system. ENJAYMO may lower the ability of your immune system to fight infections. ENJAYMO increases your chance of getting serious infections including those caused by encapsulated bacteria, including Neisseria meningitidis, Streptococcus pneumoniae, and Haemophilus influenzae type B. These serious infections may quickly become life-threatening or cause death if not recognized and treated early.

You must complete or be up to date with the vaccines against Streptococcus pneumoniae and Neisseria meningitidis at least 2 weeks before your first dose of ENJAYMO.

If your healthcare provider decides that urgent treatment with ENJAYMO is needed, you should receive vaccinations as soon as possible.

If you have been vaccinated against these bacteria in the past, you might need additional vaccines before starting ENJAYMO. Your healthcare provider will decide if you need additional vaccines.

Vaccines do not prevent all infections caused by encapsulated bacteria. Call your healthcare provider or get emergency medical care right away if you get any of these signs and symptoms of a serious infection:

fever with or without shivers or chills

fever and a rash

fever with chest pain and cough

fever with breathlessness or fast breathing

fever with high heart rate

headache with nausea or vomiting

headache and fever

headache with stiff neck or stiff back

confusion

body aches with flu-like symptoms

clammy skin

eyes sensitive to light

Infusion-related reactions: Treatment with ENJAYMO may cause infusion-related reactions, including allergic reactions that may be serious or life-threatening. Your healthcare provider may slow down or stop your ENJAYMO infusion if you have an infusion-related reaction and will treat your symptoms if needed. Tell your healthcare provider right away if you develop symptoms during your ENJAYMO infusion that may mean you are having an infusion-related reaction, including:

shortness of breath

nausea

dizziness

decrease in blood pressure

injection site reaction

rash

chest discomfort

flushing

itchy skin

rapid heartbeat

headache

Risk of autoimmune disease: ENJAYMO may increase your risk for developing an autoimmune disease such as systemic lupus erythematosus (SLE). Tell your healthcare provider and get medical help if you develop any symptoms of SLE, including:

joint pain or swelling

rash on the cheeks and nose

unexplained fever

If you have CAD and you stop receiving ENJAYMO, your healthcare provider should monitor you closely for the return of your symptoms after you stop ENJAYMO. Stopping ENJAYMO may cause the breakdown of your red blood cells due to CAD return. Symptoms or problems that can happen due to red blood cell breakdown include:

Tiredness

Rapid heart rate

Shortness of breath

Blood in your urine or dark urine

The most common side effects of ENJAYMO include:

increase in blood pressure

joint pain

dizziness

urinary tract infection

headache

feeling tired or weak

respiratory tract infection

nausea

cough

bacterial infection

runny nose

swelling in lower legs or hands

bluish color to the lips and skin

changes in color or sensation in the fingers and toes (Raynaud's phenomenon)

These are not all the possible side effects of ENJAYMO. Call your doctor for medical advice about side effects.

Before receiving ENJAYMO, tell your healthcare provider about all of your medical conditions, including if you:

have a fever or infection, including a history of human immunodeficiency virus (HIV), hepatitis B, or hepatitis C.

have an autoimmune disease such as systemic lupus erythematosus (SLE), also known as lupus.

are pregnant or plan to become pregnant. It is not known if ENJAYMO will harm your unborn baby.

are breastfeeding or plan to breastfeed. It is not known if ENJAYMO passes into your breast milk.

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

Know the medicines you take. Keep a list of them to show your healthcare provider and pharmacist when you get a new medicine.

Please see , including .

INDICATION

Back to the top